Jellinger PS, Smith DA, Mehta AE, et al; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012 Mar-Apr;18(Suppl 1):1-78. https://www.ncbi.nlm.nih.gov. Accessed 4 Sep 2013. PMID: 22522068
Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation. 2003 Jul;107(25):3124-3128. doi: 10.1161/01.CIR.0000072345.98581.24. PMID: 12835406
Ferdowsian HR, Barnard ND. Effects of plant-based diets on plasma lipids. Am J Cardiol. 2009 Oct;104(7):947-956. doi: 10.1016/j.amjcard.2009.05.032. PMID: 19766762
Grundy SM, Cleeman JL, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul;110(2):227-239. doi: 10.1161/01.CIR.0000133317.49796.0E. PMID: 15249516
American Dietetic Association. Disorders of lipid metabolism. Evidence-based nutrition practice guideline (executive summary). Academy of Nutrition and Dietetics. http://www.andeal.org/. 2011.
Institute for Clinical Systems Improvement (ICSI). ICSI health care guideline: lipid management in adults. 10th ed. ICSI. http://www.icsi.org. 2007.
International Diabetes Federation (IDF). The IDF consensus worldwide definition of the metabolic syndrome. IDF. http://www.idf.org/. Apr 2005.
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2017 Apr;23(4):479-497. doi: 10.4158/EP171764.GL. Accessed 23 Mar 2017. PMID: 28156151
Siscovick DS, Barringer TA, Fretts AM, et al; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (Fish Oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017 Apr 11;135(15):e867-e884. doi: 10.1161/CIR.0000000000000482. Accessed 23 Mar 2017. PMID: 28289069
Catapano AL, Graham I, De Backer G, et al; Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016 Oct;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Accessed 23 Mar 2017. PMID: 27567407
Ministry of Health (MOH) Singapore. MOH clinical practice guidelines on lipids. MOH Singapore. https://www.moh.gov.sg. Dec 2016. Accessed 23 Mar 2017.
Semenkovich CF, Goldberg AC, Goldberg IJ. Disorders of lipid metabolism. In: Melmed S, Polonsky KS, Larsen, PR, et al. Williams Textbook of Endocrinology. 13th ed. Philadelphia, PA: Elsevier Inc; 2016:1660-1700.
Vijan S. Screening for lipid disorders in adults. UpToDate. https://www.uptodate.com/. Dec 2016. Accessed 27 Mar 2017.
Cheung BM, Cheng CH, Lau CP, et al. 2016 Consensus statement on prevention of atherosclerotic cardiovascular disease in the Hong Kong population. Hong Kong Med J. 2017 Apr;23(2):191-201. doi: 10.12809/hkmj165045. Accessed 01 Aug 2017. PMID: 28387202
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. doi: 10.1016/j.jacc.2017.11.006. Accessed 16 Nov 2017. PMID: 29146535
Alshamiri M, Ghanaim MMA, Barter P, et al. Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. Int J Gen Med. 2018 Jul 18;11:313-322. doi: 10.2147/IJGM.S160555. Accessed 30 Jan 2019. PMID: 30050317
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Accessed 29 Jan 2019. PMID: 30423391
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Society of Cardiology (ESC). http://www.escardio.org. 31 Aug 2019. Accessed 03 Mar 2023.
Rosenson RS, Durrington P. Familial hypercholesterolemia in adults: overview. UpToDate. https://www.uptodate.com. Apr 2019. Accessed 17 Apr 2020.
Rosenson RS, Durrington P. Familial hypercholesterolemia in adults: treatment. UpToDate. https://www.uptodate.com. Nov 2019. Accessed 20 Apr 2020.
Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm – 2020 executive summary. Endocr Pract. 2020 Oct;26(10):1196-1224. doi: 10.4158/CS-2020-0490. PMID: 33471721
Rosenson RS. Low density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors. UpToDate. https://www.uptodate.com. 04 Jan 2021.
The Management of Dyslipidemia for Cardiovascular Risk Reduction Work Group. VA/DoD clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. U.S. Department of Veterans Affairs. https://www.healthquality.va.gov. Jun 2020.
Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: an expert panel position statement from HEART UK. Atherosclerosis. 2020 Nov;313:126-136. doi: 10.1016/j.atherosclerosis.2020.09.008. Accessed 22 Feb 2021. PMID: 33045618
Pereira de Moura JMDS, Pacheco Mendes PFAP, Reigota CP, et al. New drugs coming up in the field of lipid control. European Society of Cardiology (ESC). https://www.escardio.org. 16 Dec 2020.
U.S. Food & Drug Administration (US FDA). FDA approves add-on therapy for patients with genetic form of severely high cholesterol. US FDA. https://www.fda.gov. 11 Feb 2021. Accessed 02 Mar 2021.
Gonzalez-Santos LE, Oliva R, Jimeno C, et al. Executive summary of the 2020 clinical practice guidelines for the management of dyslipidemia in the Philippines: 2020 dyslipidemia CPG. Journal of the ASEAN Federation of Endocrine Societies. 2021 Mar;36(1):7-13. https://www.asean-endocrinejournal.org. Accessed 22 Mar 2021
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Circulation. 2019;140(11):e596–e646. doi: 10.1161/CIR.0000000000000678. PMID: 30879355
Visseren FLJ, Mach F, Smulders YM, et al; ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Accessed 15 Dec 2021. PMID: 34458905
Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Aug 31;78(9):960-993. doi: 10.1016/j.jacc.2021.06.011. PMID: 34332805
Writing Committee; Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Aug 23;S0735-1097(22)05594-2. doi: 10.1016/j.jacc.2022.07.006. Accessed 01 Sep 2022. PMID: 36031461
American Diabetes Association. Standards of care in diabetes - 2023. Diabetes Care. 2023 Jan;46(Suppl 1):S1-S280. https://diabetesjournals.org/. Accessed 05 Jun 2023. PMID: 36507639
Aygun S, Tokgozoglu L. Comparison of current international guidelines for the management of dyslipidemia. J Clin Med. 2022 Dec;11(23):7249. doi: 10.3390/jcm11237249. PMID: 36498823
Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021 Aug;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016. Accessed 10 Jan 2023. PMID: 33781847
Unitslab.com. Apolipoprotein B. Unitslab.com. https://unitslab.com. 2023. Accessed 03 Feb 2023.
National Heart Association of Malaysia (NHAM). Clinical practice guidelines. Management of dyslipidemia 2023. 6th ed. NHAM. https://www.malaysianheart.org. 07 Sep 2023. Accessed 27 Sep 2023.
Huang PH, Lu YW, Tsai YL, et al; Expert committee for the Taiwan Lipid Guidelines for Primary Prevention. 2022 Taiwan lipid guidelines for primary prevention. J Formos Med Assoc. 2022 Dec;121(12):2393-2407. doi: 10.1016/j.jfma.2022.05.010. Accessed 01 Feb 2024. PMID: 35715290
Khatib R, Neely D. Summary of national guidance for lipid management for primary and secondary prevention of CVD. NHS England. https://www.england.nhs.uk. Nov 2022.
Kolber MR, Klarenbach S, Cauchon M, et al. PEER simplified lipid guideline 2023 update. Prevention and management of cardiovascular disease in primary care. Can Fam Physician. 2023 Oct;69(10):675-686. doi: 10.46747/cfp.6910675. PMID: 37833089
Chiesa G, Zenti MG, Baragetti A, et al. Consensus document on lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2023 Oct;33(10):1866-1877. doi: 10.1016/j.numecd.2023.07.019. PMID: 37586921
Alhomoud IS, Talasaz A, Mehta A, et al. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies. Pharmacotherapy. 2023 Oct;43(10):1051-1063. doi: 10.1002/phar.2851. PMID: 37464942
Langlois MR, Nordestgaard BG, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020 Mar 26;58(4):496-517. doi: 10.1515/cclm-2019-1253. PMID: 31855562
Tomlinson B, Chow E. The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians. Hong Kong Med J. 2024;30:184-185. https://doi.org/10.12809/hkmj2311348.
Feingold KR. Cholesterol lowering drugs. National Library of Medicine (NIH). https://www.ncbi.nlm.nih.gov. 12 Feb 2024.
Banach M, Reiner Ž, Surma S, et al. 2024 Recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the International Lipid Expert Panel (ILEP). Drugs. 2024 Dec;84(12):1541-1577. doi: 10.1007/s40265-024-02105-5. PMID: 39497020
American Heart Association (AHA). How to get your cholesterol tested. AHA. https://www.heart.org/. 19 Feb 2024.
Centers for Disease Control and Prevention (CDC). Testing for cholesterol. CDC. https://www.cdc.gov/. 15 May 2024.
Hussain A, Virani SS, Nambi V. Hyperlipidemia. In: Levine GN. Cardiology Secrets, Sixth Edition. Philadelphia, PA: Elsevier; 2023. https://www.clinicalkey.com/. Accessed 18 Feb 2025:362-370.
National Heart, Lung, and Blood Institute (NHLBI). Blood cholesterol: diagnosis. NHLBI. https://www.nhlbi.nih.gov/. 18 Apr 2024.
Pappan N, Awosika AO, Rehman A. Dyslipidemia. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Accessed 18 Feb 2025.
Patel SB, Wyne KL, Afreen S, et al. American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025 Feb;31(2):236-262. doi: 10.1016/j.eprac.2024.09.016. PMID: 39919851
Mach F, Koskinas KC, Roeters van Lennep JE, et al; ESC/EAS Scientific Document Group. 2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025:1-20. https://doi.org/10.1093/eurheartj/ehaf190.
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 Mar;13:S0735-S1097. doi: 10.1016/j.jacc.2025.11.016. Accessed 15 Apr 2026. PMID: 41824590
Ginsberg HN, Rosenson RS, Hovingh GK, et al. LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials. J Lipid Res. 2022 Jan;63(1)(Suppl 100148). doi: 10.1016/j.jlr.2021.100148. PMID: 34774485
Ndumele CE, Rangaswami J, Chow SL, et al; American Heart Association. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2024 Mar;149(13):e1023. doi: 10.1161/CIR.0000000000001241. PMID: 37807924
